1
|
Sammarco A, Beffagna G, Sacchetto R, Vettori A, Bonsembiante F, Scarin G, Gelain ME, Cavicchioli L, Ferro S, Geroni C, Lombardi P, Zappulli V. Antitumor Effect of Berberine Analogs in a Canine Mammary Tumor Cell Line and in Zebrafish Reporters via Wnt/β-Catenin and Hippo Pathways. Biomedicines 2023; 11:3317. [PMID: 38137538 PMCID: PMC10741123 DOI: 10.3390/biomedicines11123317] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2023] [Revised: 12/07/2023] [Accepted: 12/12/2023] [Indexed: 12/24/2023] Open
Abstract
The heterogeneous nature of human breast cancer (HBC) can still lead to therapy inefficacy and high lethality, and new therapeutics as well as new spontaneous animal models are needed to benefit translational HBC research. Dogs are primarily investigated since they spontaneously develop tumors that share many features with human cancers. In recent years, different natural phytochemicals including berberine, a plant alkaloid, have been reported to have antiproliferative activity in vitro in human cancers and rodent animal models. In this study, we report the antiproliferative activity and mechanism of action of berberine, its active metabolite berberrubine, and eight analogs, on a canine mammary carcinoma cell line and in transgenic zebrafish models. We demonstrate both in vitro and in vivo the significant effects of specific analogs on cell viability via the induction of apoptosis, also identifying their role in inhibiting the Wnt/β-catenin pathway and activating the Hippo signals with a downstream reduction in CTGF expression. In particular, the berberine analogs NAX035 and NAX057 show the highest therapeutic efficacy, deserving further analyses to elucidate their mechanism of action more in detail, and in vivo studies on spontaneous neoplastic diseases are needed, aiming at improving veterinary treatments of cancer as well as translational cancer research.
Collapse
Affiliation(s)
- Alessandro Sammarco
- Department of Comparative Biomedicine and Food Science, University of Padua, 35020 Legnaro, Italy; (A.S.); (G.B.); (R.S.); (F.B.); (G.S.); (M.E.G.); (L.C.); (S.F.)
- Department of Urology, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX 77030, USA
| | - Giorgia Beffagna
- Department of Comparative Biomedicine and Food Science, University of Padua, 35020 Legnaro, Italy; (A.S.); (G.B.); (R.S.); (F.B.); (G.S.); (M.E.G.); (L.C.); (S.F.)
- Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, 35128 Padua, Italy
| | - Roberta Sacchetto
- Department of Comparative Biomedicine and Food Science, University of Padua, 35020 Legnaro, Italy; (A.S.); (G.B.); (R.S.); (F.B.); (G.S.); (M.E.G.); (L.C.); (S.F.)
| | - Andrea Vettori
- Department of Biotechnology, University of Verona, 37134 Verona, Italy;
| | - Federico Bonsembiante
- Department of Comparative Biomedicine and Food Science, University of Padua, 35020 Legnaro, Italy; (A.S.); (G.B.); (R.S.); (F.B.); (G.S.); (M.E.G.); (L.C.); (S.F.)
- Department of Animal Medicine, Production and Health, University of Padua, 35020 Legnaro, Italy
| | - Giulia Scarin
- Department of Comparative Biomedicine and Food Science, University of Padua, 35020 Legnaro, Italy; (A.S.); (G.B.); (R.S.); (F.B.); (G.S.); (M.E.G.); (L.C.); (S.F.)
| | - Maria Elena Gelain
- Department of Comparative Biomedicine and Food Science, University of Padua, 35020 Legnaro, Italy; (A.S.); (G.B.); (R.S.); (F.B.); (G.S.); (M.E.G.); (L.C.); (S.F.)
| | - Laura Cavicchioli
- Department of Comparative Biomedicine and Food Science, University of Padua, 35020 Legnaro, Italy; (A.S.); (G.B.); (R.S.); (F.B.); (G.S.); (M.E.G.); (L.C.); (S.F.)
| | - Silvia Ferro
- Department of Comparative Biomedicine and Food Science, University of Padua, 35020 Legnaro, Italy; (A.S.); (G.B.); (R.S.); (F.B.); (G.S.); (M.E.G.); (L.C.); (S.F.)
| | - Cristina Geroni
- Naxospharma Srl, 20026 Novate Milanese, Italy; (C.G.); (P.L.)
| | - Paolo Lombardi
- Naxospharma Srl, 20026 Novate Milanese, Italy; (C.G.); (P.L.)
| | - Valentina Zappulli
- Department of Comparative Biomedicine and Food Science, University of Padua, 35020 Legnaro, Italy; (A.S.); (G.B.); (R.S.); (F.B.); (G.S.); (M.E.G.); (L.C.); (S.F.)
| |
Collapse
|
2
|
Budel SJ, Penning MM, Penning LC. Hippo signaling pathway in companion animal diseases, an under investigated signaling cascade. Vet Q 2021; 41:172-180. [PMID: 33945400 PMCID: PMC8128184 DOI: 10.1080/01652176.2021.1923085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Abstract
The Hippo pathway is a highly conserved kinase cascade in mammals with the proteins YAP and TAZ as its most important downstream effectors that shuttle between cytoplasma and nucleus. It has a crucial role in processes such as embryogenesis, organ size control, homeostasis and tissue regeneration, where mechanosensing and/or cell-cell interactions are involved. As the pathway is associated with many essential functions in the body, its dysregulation is related to many diseases. In contrast to human pathology, a PubMed-search on Hippo, YAP/TAZ and companion animals (horse, equine, dog, canine, cat, feline) retrieved few publications. Because of its high level of functional conservation, it is anticipated that also in veterinary sciences aberrant Hippo YAP/TAZ signaling would be implicated in animal pathologies. Publications on Hippo YAP/TAZ in companion animals are mainly in cats and dogs and related to oncology. Here, we emphasize the important role of YAP/TAZ in liver diseases. First the liver has a remarkable regeneration capacity and a strict size control and the liver has a moderate liver cell renewal (homeostasis). The last years numerous papers show the importance of YAP/TAZ in hepatocellular carcinoma (HCC), hepatocyte differentiation and bile duct epithelial (BEC) cell survival. YAP/TAZ signaling is involved in activation of hepatic stellate cells crucial in fibrogenesis. The availability of drugs (e.g. verteporfin) targeting the YAP/TAZ pathway are described as is their potential usage in veterinary medicine. The aim of this overview is to stimulate researchers' and clinicians' interest in the potential role of Hippo YAP/TAZ signaling in veterinary medicine.
Collapse
Affiliation(s)
- Shaydee J Budel
- Department of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands
| | - Marloes M Penning
- Department of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands
| | - Louis C Penning
- Department of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands
| |
Collapse
|
3
|
Zhang J, Xu Q, Ren F, Liu Y, Cai R, Yao Y, Zhou MS. Inhibition of YAP activation attenuates renal injury and fibrosis in angiotensin II hypertensive mice. Can J Physiol Pharmacol 2021; 99:1000-1006. [PMID: 33852804 DOI: 10.1139/cjpp-2021-0033] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The Hippo/YAP (yes-associated protein) pathway is an important signaling pathway to control organ development and tissue homeostasis. YAP is a downstream effector of the Hippo pathway and a critical mediator of mechanic stress. Hypertensive nephropathy is characterized with glomerular sclerosis stiffness and renal fibrosis. The present study investigated the role of YAP pathway in angiotensin (Ang) II hypertensive renal injury by using YAP activation inhibitor verteporfin. Ang II increased the protein expression of YAP in renal nucleus fraction, decreased phospho-YAP, and phospho-LATS1/2 (large tumor suppressors 1 and 2) expressions in renal cytoplasmic fraction, suggesting Ang II activation of renal YAP. Ang II significantly increased systolic blood pressure (SBP), proteinuria, glomerular sclerosis, and fibrosis; treatment with verteporfin attenuated Ang II-induced proteinuria and renal injury with a mild reduction in SBP. Moreover, Ang II increased the protein expressions of inflammatory factors including tumor necrosis factor α, interleukin 1β, and monocyte chemoattractant protein-1, and profibrotic factors including transforming growth factor β, phospho-Smad3 and fibronectin. Verteporfin reversed abovementioned Ang II-induced molecule expressions. Our results for the first time demonstrate that the activation of the YAP pathway promotes hypertensive renal inflammation and fibrosis, which may promote hypertensive renal injury. YAP may be a new target for prevention and treatment of hypertensive renal diseases.
Collapse
Affiliation(s)
- Junjie Zhang
- Department of Physiology, Shenyang Medical College
| | - Qian Xu
- Department of Physiology, Shenyang Medical College
| | - Fu Ren
- Department of Anatomy, Shenyang Medical College, Shenyang, China, 110034
| | - Yueyang Liu
- Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, China
| | - Ruiping Cai
- Department of Physiology, Shenyang Medical College
| | - Yang Yao
- Department of Physiology, Shenyang Medical College
| | | |
Collapse
|
4
|
Sammarco A, Gomiero C, Sacchetto R, Beffagna G, Michieletto S, Orvieto E, Cavicchioli L, Gelain ME, Ferro S, Patruno M, Zappulli V. Wnt/β-Catenin and Hippo Pathway Deregulation in Mammary Tumors of Humans, Dogs, and Cats. Vet Pathol 2020; 57:774-790. [PMID: 32807036 DOI: 10.1177/0300985820948823] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Mammary cancer is a common neoplasm in women, dogs, and cats that still represents a therapeutic challenge. Wnt/β-catenin and Hippo pathways are involved in tumor progression, cell differentiation, and metastasis. The aim of this study was to evaluate mRNA and protein expression of molecules involved in these pathways in human (HBC), canine (CMT), and feline mammary tumors (FMT). Real-time quantitative polymerase chain reaction (qPCR) for β-catenin, CCND1, YAP, TAZ, CTGF, and ANKRD1, western blotting for YAP, TAZ, and β-catenin, and immunohistochemistry for estrogen receptor (ER), progesterone receptor (PR), ERBB2, β-catenin, and YAP/TAZ were performed on mammary tumor tissues. The protein expression of active β-catenin was higher in tumors than in healthy tissues in all 3 species. The mRNA expression of the downstream gene CCND1 was increased in HBC ER+ and CMTs compared to healthy tissues. Membranous and cytoplasmic protein expression of β-catenin were strongly negatively correlated in all 3 species. Tumors showed an increased protein expression of YAP/TAZ when compared to healthy tissues. Notably, YAP/TAZ expression was higher in triple negative breast cancers when compared to HBC ER+ and in FMTs when compared to CMTs. The mRNA expression of β-catenin, YAP, TAZ, CTGF, and ANKRD1 was not different between tumors and healthy mammary gland in the 3 species. This study demonstrates deregulation of Wnt/β-catenin and Hippo pathways in mammary tumors, which was more evident at the protein rather than the mRNA level. Wnt/β-catenin and Hippo pathways seem to be involved in mammary carcinogenesis and therefore represent interesting therapeutic targets that should be further investigated.
Collapse
Affiliation(s)
- Alessandro Sammarco
- Department of Comparative Biomedicine and Food Science, 9308University of Padua, Italy
| | - Chiara Gomiero
- Department of Comparative Biomedicine and Food Science, 9308University of Padua, Italy.,Department of Biomedical Sciences, 9308University of Padua, Italy.,Neuroscience Institute - Italian National Research Council (CNR), Padua, Italy
| | - Roberta Sacchetto
- Department of Comparative Biomedicine and Food Science, 9308University of Padua, Italy
| | - Giorgia Beffagna
- Department of Comparative Biomedicine and Food Science, 9308University of Padua, Italy.,Department of Cardio-Thoraco-Vascular Sciences and Public Health, 9308University of Padua, Italy
| | | | - Enrico Orvieto
- Department of Pathology, Azienda Ospedaliera di Padova, Padua, Italy.,Department of Pathology, 18674Santa Maria della Misericordia Hospital, Rovigo, Italy
| | - Laura Cavicchioli
- Department of Comparative Biomedicine and Food Science, 9308University of Padua, Italy
| | - Maria Elena Gelain
- Department of Comparative Biomedicine and Food Science, 9308University of Padua, Italy
| | - Silvia Ferro
- Department of Comparative Biomedicine and Food Science, 9308University of Padua, Italy
| | - Marco Patruno
- Department of Comparative Biomedicine and Food Science, 9308University of Padua, Italy
| | - Valentina Zappulli
- Department of Comparative Biomedicine and Food Science, 9308University of Padua, Italy
| |
Collapse
|
5
|
Sanz Ressel BL, Massone AR, Barbeito CG. Expression of the hippo signalling pathway effector YAP during canine epidermal tumourigenesis. Res Vet Sci 2020; 130:93-97. [PMID: 32155472 DOI: 10.1016/j.rvsc.2020.03.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2019] [Revised: 02/20/2020] [Accepted: 03/02/2020] [Indexed: 11/16/2022]
Abstract
Cutaneous papilloma (CP) and cutaneous squamous cell carcinoma (CSCC) are frequent epidermal tumours in dogs. In this regard, the study of the deregulated activity of signalling molecules during the epidermal tumourigenesis process could be the basis for the development of novel molecular mechanism-based antitumour treatments for CP and CSCC canine patients. Recent evidence suggests that the development and progression of CP and CSCC involve the dysregulated activation of the Hippo signalling pathway effector YAP. Thus, in the present study, we evaluated the immunohistochemical expression pattern of YAP in sections of tissue microarrays constructed from canine samples of normal epidermis, CP, preneoplastic epidermis, and CSCC. In samples of CP, preneoplastic epidermis, and CSCC, YAP expression was significantly increased relative to normal epidermis. This emerging evidence suggests that the dysregulated activity of the Hippo signalling pathway effector YAP represents a frequent event during canine epidermal tumourigenesis, pointing to this protein as a potential therapeutic target for the treatment of CP and CSCC in dogs.
Collapse
Affiliation(s)
- Berenice Liyare Sanz Ressel
- Laboratorio de Histología y Embriología Descriptiva, Experimental y Comparada (LHYEDEC), Facultad de Ciencias Veterinarias, Universidad Nacional de La Plata, La Plata, Buenos Aires, Argentina; Facultad de Ciencias Veterinarias, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Universidad Nacional de La Plata, La Plata, Buenos Aires, Argentina.
| | - Adriana Raquel Massone
- Laboratorio de Patología Especial Veterinaria Dr. Bernardo Epstein, Facultad de Ciencias Veterinarias, Universidad Nacional de La Plata, La Plata, Buenos Aires, Argentina
| | - Claudio Gustavo Barbeito
- Laboratorio de Histología y Embriología Descriptiva, Experimental y Comparada (LHYEDEC), Facultad de Ciencias Veterinarias, Universidad Nacional de La Plata, La Plata, Buenos Aires, Argentina; Facultad de Ciencias Veterinarias, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Universidad Nacional de La Plata, La Plata, Buenos Aires, Argentina
| |
Collapse
|
6
|
Luu AK, Schott CR, Jones R, Poon AC, Golding B, Hamed R, Deheshi B, Mutsaers A, Wood GA, Viloria-Petit AM. An evaluation of TAZ and YAP crosstalk with TGFβ signalling in canine osteosarcoma suggests involvement of hippo signalling in disease progression. BMC Vet Res 2018; 14:365. [PMID: 30477496 PMCID: PMC6258471 DOI: 10.1186/s12917-018-1651-5] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2018] [Accepted: 10/16/2018] [Indexed: 11/30/2022] Open
Abstract
Background Osteosarcoma (OSA) is the most common bone cancer in canines. Both transforming growth factor beta (TGFβ) and Hippo pathway mediators have important roles in bone development, stemness, and cancer progression. The role of Hippo signalling effectors TAZ and YAP has never been addressed in canine OSA. Further, the cooperative role of TGFβ and Hippo signalling has yet to be explored in osteosarcoma. To address these gaps, this study investigated the prognostic value of TAZ and YAP alone and in combination with pSmad2 (a marker of active TGFβ signalling), as well as the involvement of a TGFβ-Hippo signalling crosstalk in tumourigenic properties of OSA cells in vitro. An in-house trial tissue microarray (TMA) which contained 16 canine appendicular OSA cases undergoing standard care and accompanying follow-up was used to explore the prognostic role of TAZ, YAP and pSmad2. Published datasets were used to test associations between TAZ and YAP mRNA levels, metastasis, and disease recurrence. Small interfering RNAs specific to TAZ and YAP were utilized in vitro alone or in combination with TGFβ treatment to determine their role in OSA viability, proliferation and migration. Results Patients with low levels of both YAP and pSmad2 when evaluated in combination had a significantly longer time to metastasis (log-rank test, p = 0.0058) and a longer overall survival (log rank test, p = 0.0002). No similar associations were found for TAZ and YAP mRNA levels. In vitro, TAZ knockdown significantly decreased cell viability, proliferation, and migration in metastatic cell lines, while YAP knockdown significantly decreased viability in three cell lines, and migration in two cell lines, derived from either primary tumours or their metastases. The impact of TGFβ signaling activation on these effects was cell line-dependent. Conclusions YAP and pSmad2 have potential prognostic value in canine appendicular osteosarcoma. Inhibiting YAP and TAZ function could lead to a decrease in viability, proliferation, and migratory capacity of canine OSA cells. Assessment of YAP and pSmad2 in larger patient cohorts in future studies are needed to further elucidate the role of TGFβ-Hippo signalling crosstalk in canine OSA progression. Electronic supplementary material The online version of this article (10.1186/s12917-018-1651-5) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Anita K Luu
- Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, 50 Stone Road East, Guelph, ON, N1G 2W1, Canada
| | - Courtney R Schott
- Department of Pathobiology, Ontario Veterinary College, University of Guelph, 50 Stone Road East, Guelph, ON, N1G 2W1, Canada
| | - Robert Jones
- Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, 50 Stone Road East, Guelph, ON, N1G 2W1, Canada
| | - Andrew C Poon
- Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, 50 Stone Road East, Guelph, ON, N1G 2W1, Canada
| | - Brandon Golding
- Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, 50 Stone Road East, Guelph, ON, N1G 2W1, Canada
| | - Roa'a Hamed
- Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, 50 Stone Road East, Guelph, ON, N1G 2W1, Canada
| | - Benjamin Deheshi
- Medical City Forth Worth, HCA affiliated Hospital, 900 8th Ave, Fort Worth, TX, 76104, USA
| | - Anthony Mutsaers
- Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, 50 Stone Road East, Guelph, ON, N1G 2W1, Canada
| | - Geoffrey A Wood
- Department of Pathobiology, Ontario Veterinary College, University of Guelph, 50 Stone Road East, Guelph, ON, N1G 2W1, Canada.
| | - Alicia M Viloria-Petit
- Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, 50 Stone Road East, Guelph, ON, N1G 2W1, Canada.
| |
Collapse
|
7
|
Rico C, Boerboom D, Paquet M. Expression of the Hippo signalling effectors YAP and TAZ in canine mammary gland hyperplasia and malignant transformation of mammary tumours. Vet Comp Oncol 2018; 16:630-635. [PMID: 30117264 DOI: 10.1111/vco.12432] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2018] [Revised: 06/28/2018] [Accepted: 06/29/2018] [Indexed: 12/19/2022]
Abstract
Canine mammary tumours (CMTs) are common neoplasms in dogs that feature many of the clinical, genetic and molecular characteristics of human breast cancer. Despite their high metastatic potential, few adjuvant chemotherapeutic treatment options exist for malignant CMTs, and the development of novel, targeted pharmacological approaches will require a better understanding of their pathogenesis. As recent evidence suggests that dysregulated Hippo signalling is involved in the development and progression of breast cancer, we sought to determine if this pathway could also play a role in CMT. The expression of the Hippo signalling effectors YAP and TAZ was analysed by immunoblotting and immunohistochemistry in samples including normal mammary gland, lobular hyperplasia, benign tumours and malignant tumours of all grades. We found a significant increase in TAZ (but not YAP) expression occurred in lobular hyperplasia relative to normal mammary gland, suggesting a role for TAZ in non-neoplastic epithelial proliferation. Nuclear expression of both TAZ and YAP were significantly higher in malignant tumours than in benign ones, suggesting that Hippo dysregulation could play a role in CMT malignant transformation. No differences in YAP or TAZ expression were detected between grades of malignant tumours. Together, our results indicate that alterations in Hippo signalling may play a role in the pathogenesis of CMT, in a manner similar to breast cancer. Hippo pathway components may therefore represent targets for the development of novel chemotherapeutic agents that could be useful for the treatment of both the human and canine diseases.
Collapse
Affiliation(s)
- Charlène Rico
- Centre de Recherche en Reproduction et Fertilité, Université de Montréal, Québec, Canada
- Département de Biomédecine Vétérinaire, Université de Montréal, Québec, Canada
| | - Derek Boerboom
- Centre de Recherche en Reproduction et Fertilité, Université de Montréal, Québec, Canada
- Département de Biomédecine Vétérinaire, Université de Montréal, Québec, Canada
| | - Marilène Paquet
- Centre de Recherche en Reproduction et Fertilité, Université de Montréal, Québec, Canada
- Département de Pathologie et de Microbiologie, Université de Montréal, Québec, Canada
| |
Collapse
|
8
|
Gareau A, Rico C, Boerboom D, Nadeau ME. In vitro efficacy of a first-generation valosin-containing protein inhibitor (CB-5083) against canine lymphoma. Vet Comp Oncol 2018; 16:311-317. [PMID: 29314493 DOI: 10.1111/vco.12380] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2017] [Revised: 11/27/2017] [Accepted: 11/28/2017] [Indexed: 11/26/2022]
Abstract
Valosin-containing protein (VCP), through its critical role in the maintenance of protein homeostasis, is a promising target for the treatment of several malignancies, including canine lymphoma. CB-5083, a first-in-class VCP inhibitor, exerts cytotoxicity through the induction of irreversible proteotoxic stress and possesses a broad spectrum of anticancer activity. Here, we determined the cytotoxicity CB-5083 in canine lymphoma cells and its mechanism of action in vitro. Canine lymphoma cell lines were treated with varying concentrations of CB-5083 and assessed for viability by trypan blue exclusion and apoptosis by caspase activity assays. The mechanism of CB-5083 action was determined by immunoblotting and RT-qPCR analyses of Lys48 ubiquitination and markers of ER stress (DDIT3), autophagy (SQSTM1, MAP1LC3A) and DNA damage (γH2AX). Unfolded protein response markers were also evaluated by immunoblotting (eIF2α, P-eIF2α) and RT-qPCR (ATF4). CB-5083 treatment resulted in preferential cytotoxicity in canine lymphoma cell lines over control peripheral blood mononuclear cells. CB-5083 rapidly disrupted the ubiquitin-dependent protein degradation system, inducing sustained ER stress as indicated by a dramatic increase in DDIT3. Activation of the unfolded protein response occurred through the increase eIF2α phosphorylation and increased transcription of ATF4, but did not re-establish protein homeostasis. Cells rapidly underwent apoptosis through activation of the caspase cascade. These results further validate VCP as an attractive target for the treatment of canine lymphoma and identify CB-5083 as a novel therapy with clinical potential for this malignancy.
Collapse
Affiliation(s)
- A Gareau
- Faculté de Médecine vétérinaire, Université de Montreal, St-Hyacinthe, Québec, Canada J2C 7C6
| | - C Rico
- Faculté de Médecine vétérinaire, Université de Montreal, St-Hyacinthe, Québec, Canada J2C 7C6
| | - D Boerboom
- Faculté de Médecine vétérinaire, Université de Montreal, St-Hyacinthe, Québec, Canada J2C 7C6
| | - M-E Nadeau
- Faculté de Médecine vétérinaire, Université de Montreal, St-Hyacinthe, Québec, Canada J2C 7C6
| |
Collapse
|